These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1114 related items for PubMed ID: 28583305

  • 21. A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
    López P, Arguedas Mohs A, Abdelnour Vásquez A, Consuelo-Miranda M, Feroldi E, Noriega F, Jordanov E, B Chir S, Zambrano B.
    Pediatr Infect Dis J; 2017 Nov; 36(11):e272-e282. PubMed ID: 28719500
    [Abstract] [Full Text] [Related]

  • 22. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers.
    Quiambao B, Van Der Meeren O, Kolhe D, Gatchalian S.
    Hum Vaccin Immunother; 2012 Mar; 8(3):347-54. PubMed ID: 22330958
    [Abstract] [Full Text] [Related]

  • 23. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA, Assudani D, Kuriyakose S, Van Der Meeren O.
    Hum Vaccin Immunother; 2014 Mar; 10(10):2795-8. PubMed ID: 25483640
    [Abstract] [Full Text] [Related]

  • 24. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
    Zepp F, Knuf M, Heininger U, Jahn K, Collard A, Habermehl P, Schuerman L, Sänger R.
    Vaccine; 2004 Jun 02; 22(17-18):2226-33. PubMed ID: 15149781
    [Abstract] [Full Text] [Related]

  • 25. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ.
    Vaccine; 2006 May 29; 24(22):4727-36. PubMed ID: 16616973
    [Abstract] [Full Text] [Related]

  • 26. Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan.
    Nakayama T, Vidor E, Tsuzuki D, Nishina S, Sasaki T, Ishii Y, Mizukami H, Tsuge H.
    J Infect Chemother; 2020 Jul 29; 26(7):651-659. PubMed ID: 32307307
    [Abstract] [Full Text] [Related]

  • 27. Immunogenicity, Safety and Reactogenicity of a Booster Dose of the 10-Valent Pneumococcal Nontypeable H. influenzae Protein D Conjugate Vaccine Coadministered With DTPa-IPV-Hib in Dutch Children: A Randomized Controlled Trial.
    van den Bergh MR, Spijkerman J, François N, Swinnen K, Borys D, Schuerman L, Veenhoven RH, Sanders EA.
    Pediatr Infect Dis J; 2016 Jul 29; 35(7):e206-19. PubMed ID: 27097348
    [Abstract] [Full Text] [Related]

  • 28. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine.
    Gimenez-Sanchez F, Kieninger DM, Kueper K, Martinon-Torres F, Bernaola E, Diez-Domingo J, Steul K, Juergens C, Gurtman A, Giardina P, Liang JZ, Gruber WC, Emini EA, Scott DA, 501 and 006 study groups.
    Vaccine; 2011 Aug 11; 29(35):6042-8. PubMed ID: 21704105
    [Abstract] [Full Text] [Related]

  • 29. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T, Forstén A, Desole MG, Ferrera G, Caubet M, Mesaros N, Boutriau D.
    Pediatr Infect Dis J; 2013 May 11; 32(5):521-9. PubMed ID: 23190785
    [Abstract] [Full Text] [Related]

  • 30. Differences by sex in IgG levels following infant and childhood vaccinations: An individual participant data meta-analysis of vaccination studies.
    Boef AGC, van der Klis FRM, Berbers GAM, Buisman AM, Sanders EAM, Kemmeren JM, van der Ende A, de Melker HE, Rots NY, Knol MJ.
    Vaccine; 2018 Jan 08; 36(3):400-407. PubMed ID: 29223483
    [Abstract] [Full Text] [Related]

  • 31. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S, Palestroque E, De Vleeschauwer I, Han HH, Poolman J, Schuerman L, Dobbelaere K, Boutriau D.
    Int J Infect Dis; 2008 May 08; 12(3):278-88. PubMed ID: 17981067
    [Abstract] [Full Text] [Related]

  • 32. Immunogenicity and reactogenicity of DTPa-IPV/Hib vaccine co-administered with hepatitis B vaccine for primary and booster vaccination of Taiwanese infants.
    Shao PL, Lu CY, Hsieh YC, Bock HL, Huang LM, Taiwan Infanrix-069 Study Group.
    J Formos Med Assoc; 2011 Jun 08; 110(6):415-22. PubMed ID: 21741011
    [Abstract] [Full Text] [Related]

  • 33. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.
    Halperin SA, Langley JM, Hesley TM, Zappacosta PS, Radley D, Smith B, Hoffenbach A, Boslego J, Silber JL.
    Hum Vaccin; 2005 Jun 08; 1(6):245-50. PubMed ID: 17012871
    [Abstract] [Full Text] [Related]

  • 34. Infant vaccine co-administration: review of 18 years of experience with GSK's hexavalent vaccine co-administered with routine childhood vaccines.
    Dolhain J, Janssens W, Dindore V, Mihalyi A.
    Expert Rev Vaccines; 2020 May 08; 19(5):419-443. PubMed ID: 32419537
    [Abstract] [Full Text] [Related]

  • 35. Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series.
    Oliver JL, Sadorge C, Boisnard F, Snape MD, Tomlinson R, Mann R, Rudd P, Bhakthavalsala S, Faust SN, Heath PT, Hughes SM, Borrow R, Thomas S, Finn A.
    Vaccine; 2020 Jul 31; 38(35):5718-5725. PubMed ID: 32654902
    [Abstract] [Full Text] [Related]

  • 36. Immunogenicity and Safety of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T, bOPV, and IPV Vaccines Administered at 2, 4, 6 Months of Age Concomitantly With Rotavirus and Pneumococcal Conjugate Vaccines in Healthy Infants in Thailand.
    Sanchez L, Rungmaitree S, Kosalaraksa P, Jantarabenjakul W, Leclercq J, Yaiprayoon Y, Midde VJ, Varghese K, Mangarule S, Noriega F.
    Pediatr Infect Dis J; 2023 Aug 01; 42(8):711-718. PubMed ID: 37257121
    [Abstract] [Full Text] [Related]

  • 37. A prospective, observational, multi-center, post-marketing safety surveillance study of the GSK combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b invasive infections (DTaP-IPV/Hib) in South Korean infants.
    Elenge DM, Heo JS, Kim SS, Kim YK, Lee JH, Xavier S, Bahar E, Dos Santos G, Guignard A.
    Hum Vaccin Immunother; 2024 Dec 31; 20(1):2406060. PubMed ID: 39376187
    [Abstract] [Full Text] [Related]

  • 38. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
    Martinón-Torres F, Gimenez-Sanchez F, Gurtman A, Bernaola E, Diez-Domingo J, Carmona A, Sidhu M, Sarkozy DA, Gruber WC, Emini EA, Scott DA, 3007 Study Group.
    Pediatr Infect Dis J; 2012 Apr 31; 31(4):392-9. PubMed ID: 22301472
    [Abstract] [Full Text] [Related]

  • 39. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M, Zambrano B, Santos-Lima E.
    Pediatr Infect Dis J; 2012 Jan 31; 31(1):e24-30. PubMed ID: 22157567
    [Abstract] [Full Text] [Related]

  • 40. Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age.
    Avdicova M, Crasta PD, Hardt K, Kovac M.
    Vaccine; 2015 May 28; 33(23):2727-33. PubMed ID: 24962750
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 56.